LeadIQ logo
Learn more at LeadIQ.com

Insights

Loading spinner
Gathering insights about Ophirex, Inc.

Similar companies to Ophirex, Inc.

Ophirex, Inc. Tech Stack

Ophirex, Inc. uses 8 technology products and services including Google Analytics, Google Font API, Stimulus, and more. Explore Ophirex, Inc.'s tech stack below.

  • Google Analytics
    Analytics
  • Google Font API
    Font Scripts
  • Stimulus
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • Webflow
    Page Builders
  • Amazon Web Services
    Platform As A Service
  • OpenResty
    Web Servers

Ophirex, Inc.'s Email Address Formats

Ophirex, Inc. uses at least 1 format(s):
Ophirex, Inc. Email FormatsExamplePercentage
First@ophirex.comJohn@ophirex.com
50%
First@ophirex.comJohn@ophirex.com
50%

Frequently Asked Questions

Where is Ophirex, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Ophirex, Inc.'s main headquarters is located at Corte Madera, CA 94925 US. The company has employees across 2 continents, including North AmericaEurope.

What is Ophirex, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Ophirex, Inc.'s official website is ophirex.com and has social profiles on LinkedIn.

How much revenue does Ophirex, Inc. generate?

Minus sign iconPlus sign icon
As of November 2024, Ophirex, Inc.'s annual revenue reached $1.8M.

What is Ophirex, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Ophirex, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ophirex, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2024, Ophirex, Inc. has approximately 25 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: J. G.Chief Medical Officer: T. P.Vice President Finance: K. D.. Explore Ophirex, Inc.'s employee directory with LeadIQ.

What industry does Ophirex, Inc. belong to?

Minus sign iconPlus sign icon
Ophirex, Inc. operates in the Biotechnology Research industry.

What technology does Ophirex, Inc. use?

Minus sign iconPlus sign icon
Ophirex, Inc.'s tech stack includes Google AnalyticsGoogle Font APIStimulusjQueryOpen GraphWebflowAmazon Web ServicesOpenResty.

What is Ophirex, Inc.'s email format?

Minus sign iconPlus sign icon
Ophirex, Inc.'s email format typically follows the pattern of . Find more Ophirex, Inc. email formats with LeadIQ.

How much funding has Ophirex, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2024, Ophirex, Inc. has raised $37M in funding. The last funding round occurred on Jan 05, 2023 for $37M.

When was Ophirex, Inc. founded?

Minus sign iconPlus sign icon
Ophirex, Inc. was founded in 2015.
Ophirex, Inc.

Ophirex, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Ophirex, Inc., a Public Benefit Corp. focused on treatments for acute, life-threatening illnesses, is modernizing the treatment of snakebite victims by developing an affordable, accessible, oral treatment for immediate use anywhere a snake’s bite occurs.

Approximately 80% of the world’s population lives in close proximity to at least one venomous snake species and more than 500,000 people are killed or maimed by snakes each year worldwide.[1][2] Field treatments could help save hundreds of thousands of lives and limbs annually and provide enormous savings in healthcare costs.[2][3]

Ophirex is developing a “time of bite” oral snakebite treatment that blocks the most commonly lethal component of snake venom—present in 95% of the world’s venomous snakes.[4] This antidote—now in human clinical trials—can be administered immediately in the field or in the hospital to effectively stop the venom’s devastating assault.[5][6][7]

1. Vulnerability to snakebite envenoming: a global mapping of hotspots. www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31224-8/fulltext
2. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. https://doi.org/10.1371/journal.pntd.0007059
3. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. www.ajtmh.org/view/journals/tpmd/99/2/article-p404.xml
4. A Review and Database of Snake Venom Proteomes. https://pubmed.ncbi.nlm.nih.gov/28927001/
5. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. https://pubmed.ncbi.nlm.nih.gov/27571102/
6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. www.ncbi.nlm.nih.gov/pmc/articles/PMC7076770/
7. Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO).
https://clinicaltrials.gov/ct2/show/NCT04996264

Section iconCompany Overview

Headquarters
Corte Madera, CA 94925 US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $37M

    Ophirex, Inc. has raised a total of $37M of funding over 2 rounds. Their latest funding round was raised on Jan 05, 2023 in the amount of $37M.

  • $10M

    Ophirex, Inc.'s revenue is in the range of $10M

Section iconFunding & Financials

  • $37M

    Ophirex, Inc. has raised a total of $37M of funding over 2 rounds. Their latest funding round was raised on Jan 05, 2023 in the amount of $37M.

  • $10M

    Ophirex, Inc.'s revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.